DUBLIN – Finnish-Swiss firm Aurealis Pharma AG is spinning out its lead asset, AUP-16, a genetically engineered bacterial species in development for diabetic foot ulcer, into a new company, Aurealis Therapeutics AG, which has raised CHF7.8 million (US$7.8 million) in new cash to finance an upcoming phase I/IIa trial of the three-in-one combination therapy.